NCT04623255View on ClinicalTrials.gov

Study of Plasma Exchange in Severe COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
COVID19
Interventions
DRUG

OCTAPLAS

plasma exchange

Trial Locations (1)

NW1 2PG

University College London Hospital, London

All Listed Sponsors
lead

University College, London

OTHER

NCT04623255 - Study of Plasma Exchange in Severe COVID-19 | Biotech Hunter | Biotech Hunter